Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity

Beatrice Greco, MSc, Katia Paolella, Barbara Camisa, Valeria Malacarne, PhD, Laura Falcone, Andrea Graziani, PhD, Chiara Bonini, MD, Attilio Bondanza, MD, Monica Casucci, PhD

Blood (2018) 132 (Supplement 1): 4544.

https://doi.org/10.1182/blood-2018-99-116019

Published: 2018

Journal Articles

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Matteo Giovanni Carrabba, MD, Monica Casucci, PhD, Michael Hudecek, MD, Concetta Quintarelli, PhD, Javier Briones, MD, Roman Hajek, MD PhD, Jorge Sierra, MD, Franco Locatelli, Hermann Einsele, MD PhD, Claudio Bordignon, MD, Fabio Ciceri, MD, Catia Traversari, PhD

Blood (2018) 132 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2018-99-117974

Published: 2018

Journal Articles

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Francesco Manfredi, MD, Maddalena Noviello, PhD, Eliana Ruggiero, PhD, Tommaso Perini, MD, Giacomo Oliveira, PhD, Filippo Cortesi, PhD, Pantaleo De Simone, MD, Cristina Toffalori, Valentina Gambacorta, MSc, Raffaella Greco, MD, Jacopo Peccatori, Monica Casucci, PhD, Giulia Casorati, PhD, Paolo Dellabona, MD PhD, Nicoletta Cieri, MD PhD, Attilio Bondanza, MD, Luca Vago, MD PhD, Fabio Ciceri, MD, Chiara Bonini, MD

Blood (2018) 132 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2018-99-118104

Published: 2018

Journal Articles

Monocytes Are Required for Both Optimal Anti-Leukemic Efficacy and the Cytokine Release Syndrome By CAR-T Cells: Lessons from an Innovative Xenotolerant Mouse Model

Margherita Norelli, MSc, Monica Casucci, PhD, Barbara Camisa, BSc, Laura Falcone, MSc, Catia Traversari, PhD, Claudio Bordignon, MD, Fabio Ciceri, MD, Chiara Bonini, MD, Attilio Bondanza, MD PhD

Blood (2016) 128 (22): 997.

https://doi.org/10.1182/blood.V128.22.997.997

Published: 2016

Journal Articles

Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells

Monica Casucci, PhD, Benedetta Nicolis di Robilant, MSc, Laura Falcone, MSc, Barbara Camisa, BSc, Margherita Norelli, Bsc, Bernhard Gentner, MD, Pietro Genovese, PhD, Maurilio Ponzoni, MD, Aurore Saudemont, PhD, Claudio Bordignon, MD, Luigi Naldini, MD, PhD, Fabio Ciceri, MD, Gianpietro Dotti, MD, Chiara Bonini, MD, Attilio Bondanza, MD, PhD

Blood (2013) 122 (21): 142.

https://doi.org/10.1182/blood.V122.21.142.142

Published: 2013

Journal Articles

CD44v6 Is Required For In Vivo Tumorigenesis Of Human AML and MM Cells: Role Of Microenvironmental Signals and Therapeutic Implications

Benedetta Nicolis di Robilant, MSc, Monica Casucci, PhD, Laura Falcone, MSc, Barbara Camisa, BSc, Bernhard Gentner, MD#, Luigi Naldini, MD, PhD#, Claudio Bordignon, MD, Fabio Ciceri, MD, Chiara Bonini, MD, Attilio Bondanza, MD, PhD

Blood (2013) 122 (21): 605.

https://doi.org/10.1182/blood.V122.21.605.605

Published: 2013

Journal Articles

Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication

Monica Casucci, PhD, Benedetta Nicolis di Robilant, MSc, Laura Falcone, MSc, Barbara Camisa, BSc, Pietro Genovese, PhD, Bernhard Gentner, MD $, Luigi Naldini, MD, PhD, Barbara Savoldo, MD, PhD, Fabio Ciceri, MD, Claudio Bordignon, MD, Gianpietro Dotti, MD, Chiara Bonini, MD, Attilio Bondanza, MD, PhD

Blood (2012) 120 (21): 949.

https://doi.org/10.1182/blood.V120.21.949.949

Published: 2012

NARROW

Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Monocytes Are Required for Both Optimal Anti-Leukemic Efficacy and the Cytokine Release Syndrome By CAR-T Cells: Lessons from an Innovative Xenotolerant Mouse Model

Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells

CD44v6 Is Required For In Vivo Tumorigenesis Of Human AML and MM Cells: Role Of Microenvironmental Signals and Therapeutic Implications

Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication

Email alerts

ASH Publications

American Society of Hematology

Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Monocytes Are Required for Both Optimal Anti-Leukemic Efficacy and the Cytokine Release Syndrome By CAR-T Cells: Lessons from an Innovative Xenotolerant Mouse Model

Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells

CD44v6 Is Required For In Vivo Tumorigenesis Of Human AML and MM Cells: Role Of Microenvironmental Signals and Therapeutic Implications

Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only